You are here: Industry Insights > BRIDGE

News List

Bridge Biotherapeutics Announces the Initiation of Patient Dosing in the Proof of Clinical Principle Study for BBT-401, an Investigational Drug for Ulcerative Colitis prnasia
June 15, 2021
Bridge Biotherapeutics (KQ288330) announced the first patient dosing of BBT-401 at mid to high doses in its proof of clinical principle (PoCP) study to examine the drug's efficacy and safety in active ulcerative colitis (NCT04596293).
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site prnasia
June 02, 2021
Bridge Biotherapeutics today announced the first patient dosing of BBT-401 in its open label, proof of mechanism study to examine the drug's efficacy and safety in active ulcerative colitis when delivered rectally to the colon (NCT04478825).
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S prnasia
April 07, 2021
Bridge Biotherapeutics Inc., a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity of BBT-176 in ...
59 Thought Leaders Present Their Findings on How to 'Bridge the Digital Gap' After COVID prnewswire
July 02, 2020
The journey towards the digital world is accelerating in today's challenging environment and the consumer is evolving at a speed never seen before.
Boehringer Ingelheim, Bridge Biotherapeutics to Collaborate on IPF Pipeline contractpharma
July 24, 2019
Global license agreement aims to develop Bridge Biotherapeutics’ autotaxin inhibitor, BBT-877.
BridgeBio Pharma Enters Genetic Disease Alliance contractpharma
November 13, 2018
BridgeBio Pharma Enters Genetic Disease Alliance